In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Purdue Battles Generics, Early

Executive Summary

The envy that many people in the biotech and pharma industry felt in the late 1990s when Purdue Pharma's revenues skyrocketed on sales of OxyContin was replaced by compassion, as the company struggled to deal with illegal use and abuse of the painkiller. Now Purdue is battlling a court ruling--sparked by would-be generic competitor Endo Pharmaceuticals--that finds the patents on Purdue's most important product are unenforceable. The company is confident it will prevail and enjoy another nine years of patent protection for OxyContin.

You may also be interested in...

Authorized Generics: Band-Aid or Strategy?

In the past two years, some Big Pharma companies have revitalized their long-dormant generics activities and launched generic copies of their own drugs. They're doing this to capture business they would otherwise lose completely and to tie up generics competitors in court. While similar strategies failed in the past, a number of changes may make it more feasible. Innovators are behaving more rationally about pricing. And they are going after the most lucrative part of the generics business.

Pain Therapeutics' Window of Opportunity

Pain Therapeutics Inc., which started up in 1998 and went public just two years later in a hot market, thinks it can turn Purdue Pharma's patent problems to its own advantage-and go it one better. Long before the OxyContin patents were deemed invalid, Purdue was struggling with the fact that its extended-release painkiller had become a drug of abuse. People looking for a quick high found they could get one by crushing "Oxies" or dissolving them in alcohol--thus circumventing the innovation in formulation that made OxyContin so effective at treating pain. Pain Therapeutics believes it has a way around the abuse problem.

Purdue's OxyContin: A Blessing and a Curse

Purdue Pharma's best-selling opioid painkiller, OxyContin, is starting to look more like a curse than a blessing to the company as incidents of its abuse rise. The drug is being sold on the street like a narcotic, and publicity about pharmacies being robbed and overdose deaths caused by OxyContin could hurt sales. Purdue's not the first pharma company to stand accused of doing bad while trying to do good. But the company is frustrated, even as it takes precautions to stem abusive use of its product.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts